Purchase this article with an account.
L. Wu, T. Evans, J. F. Arevalo, M. H. Berrocal, J. A. Roca, M. Maia, R. Costa, J. Cardillo, F. J. Rodriguez, Pan American Collaborative Retina Study Group (PACORES); Short Term Visual and Anatomic Outcomes Following Intravitreal Bevacizumab in the Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion. Invest. Ophthalmol. Vis. Sci. 2007;48(13):1547. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To describe the short term visual and anatomic outcomes of an intravitreal injection of 1.25 mg or 2.5 mg of bevacizumab in eyes with macular edema secondary to central retinal vein occlusion.
Interventional retrospective multicenter case series of 52 eyes with macular edema secondary to central retinal vein occlusion treated with an intravitreal injection of either 1.25 mg or 2.5 mg of bevacizumab. Visual acuity, ophthalmoscopic, fluorescein angiographic and OCT findings were recorded at baseline and last follow-up.
After an average follow-up of 23.3 weeks (range 4 to 56 weeks), the baseline logMAR visual acuity improved from 1.40 ± 0.60 to 1.10 ± 0.69 at 1 month (p=0.0331), 1.18 ± 0.65 at 3 months (p<0.0006), 1.09 ± 0.68 at 6 months (p=0.0574) and 1.12 ± 0.68 (p=0.0414) at the last follow up. Central macular thickness decreased from 566 ± 239 µm to 306 ± 102 µm (p<0.0001) at 1 month, 360 ± 213 µm at 3 months (p<0.0001), 247 ± 189 µm at 6 months (p<0.0001) and 305 ± 159 µm (p<0.0001) at the last follow-up. On average, patients received 1.9 injections per eye (range 1 to 6). Eighteen eyes (35%) received 2 injections at a mean of 8 weeks, 10 eyes (19%) 3 injections, 2 eyes (3.8%) 4 injections and one eye (1.9%) 6 injections. At the last follow-up, 23 eyes (44.2%) remained within 2 lines of baseline VA, 24 eyes (46.2%) improved 3 or more lines of ETDRS VA and 5 (9.6%) lost more than 3 lines of ETDRS VA. All 12 eyes with baseline rubeosis iridis or retinal neovascularization had disappearance of their neovascularization following the bevacizumab injection. No ocular or systemic complications were reported.
Despite the small number of eyes and the short follow up in this series, it appears that intravitreal injections of bevacizumab might be a useful treatment in this condition.
This PDF is available to Subscribers Only